Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Clarian Health Partners |
---|---|
Information provided by: | National Institute on Aging (NIA) |
ClinicalTrials.gov Identifier: | NCT00182884 |
The purpose of this study is to explore the efficacy of a perioperative daily dose of Donepezil (a cholinergic enhancer) in reducing the incidence and severity of delirium.
Condition | Intervention | Phase |
---|---|---|
Postoperative Complications Delirium |
Drug: Donepezil |
Phase IV |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double-Blind, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Preventing Delirium in Hospitalized Elderly |
Estimated Enrollment: | 30 |
Study Start Date: | July 2004 |
Study Completion Date: | April 2007 |
Primary Completion Date: | April 2007 (Final data collection date for primary outcome measure) |
Delirium is confusion or a sudden change in alertness which may happen after hip repair surgery. Up to 65% of elderly undergoing surgical repair of hip fracture experience post-operative delirium. These individuals often stay in the hospital longer, have more complications, and are more likely to die. Early studies suggest that delirium could be prevented by correcting the central cholinergic deficit that is associated with delirium. Donepezil is currently being used to treat memory loss in patients with Alzheimer's disease.
This study will recruit 30 adults aged 65 or older who are undergoing hip fracture surgery. Participants will be randomized to receive either Donepezil or a matching placebo within 24 hours prior to surgery and for 4 days after the surgery.
All material to be collected will be from interviews, questionnaires, and medical chart review at baseline and daily for the entire hospital stay. The Confusion Assessment Method (CAM) and Memorial Delirium Assessment Scale (MDAS) will be used to evaluate the effect of Donepezil on delirium incidence and severity. Other assessments include cognitive deficit, length of hospitalization, discharge site, adverse effects, and psychotropic medications.
Ages Eligible for Study: | 65 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, Indiana | |
Methodist Hospital, Clarian Health Partners | |
Indianapolis, Indiana, United States, 46202 |
Principal Investigator: | Malaz Boustani, MD, MPH | Regenstrief Institute, Indiana University Center for Aging Research |
Study ID Numbers: | IA0079, VFR-161 |
Study First Received: | September 9, 2005 |
Last Updated: | February 28, 2008 |
ClinicalTrials.gov Identifier: | NCT00182884 |
Health Authority: | United States: Federal Government |
Hospital acquired complications adverse effects Cognitive Impairment Aging |
Signs and Symptoms Delirium, Dementia, Amnestic, Cognitive Disorders Postoperative Complications Mental Disorders Donepezil Neurologic Manifestations |
Confusion Dementia Neurobehavioral Manifestations Cognition Disorders Delirium |
Nootropic Agents Cholinesterase Inhibitors Neurotransmitter Agents Pathologic Processes Molecular Mechanisms of Pharmacological Action Therapeutic Uses |
Physiological Effects of Drugs Nervous System Diseases Enzyme Inhibitors Cholinergic Agents Central Nervous System Agents Pharmacologic Actions |